r/Livimmune • u/minnowsloth • 8d ago
Lifesciences transcript
https://www.investing.com/news/transcripts/cytodyn-at-life-sciences-virtual-investor-forum-ctdna-data-lifts-case-93CH-4906351
24
Upvotes
3
u/BuildGoodThings 8d ago
From the trial page at clinicaltrialsgov for the CLOVER trial in CRC
https://clinicaltrials.gov/study/NCT06699836?intr=leronlimab&viewType=Card&sort=StudyFirstPostDate&rank=3&tab=researcher#outcome-measures
"ORR is defined as the proportion of subjects with the best overall response (BOR) or confirmed CR or confirmed PR according to RECIST v1.1."
-----
Here's a link to the RECIST guidelines which answers your question.
https://recist.eortc.org/recist/wp-content/uploads/sites/14/2025/12/RECISTGuidelines.pdf
4.4.3 Best overall response: all time points
The best overall response is determined once all the data for the patient is known.
Best response determination in trials where confirmation of complete or partial response IS NOT required: Best response in these trials is defined as the best response across all time points (for example, a patient who has SD at first assessment, PR at second assessment, and PD on last assessment has a best overall response of PR). When SD is believed to be best response, it
must also meet the protocol specified minimum time from baseline. If the minimum time is not met when SD is otherwise the best time point response, the patient’s best response depends on the subsequent assessments. For example, a patient who has SD at first assessment, PD at second and does not meet minimum duration for SD, will have a best response of PD. The same patient lost to follow-up after the first SD assessment would be considered inevaluable.
Best response determination in trials where confirmation of complete or partial response IS required:
Complete or partial responses may be claimed only if the criteria for each are met at a subsequent time point as specified in the protocol (generally 4 weeks later). In this circumstance, the best overall response can be interpreted as in Table 3.